pCDCAR1 gp100 h(γ), T (CAR-T-1-M552-G)

The vector of anti-gp100 chimeric antigen receptor(CAR) is constructed for the engineering of T cell to target human gp100. The T cell is genetically modified through transduction with a lentiviral vector expressing anti-gp100 VHH linked to FcεRIγ signaling domains. And the vector product was designed for the treatment of melanoma.

Datasheet   Add to Cart


  • Target
  • gp100
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Melanoma
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • VHH-FcεRIγ
  • Discription of Signaling Cassetes
  • FcεRIγ
    The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE). FcεRI is a key molecule involved in allergic reactions. It is a tetramer composed of 1alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors. The scFv-based CARs engineered to contain a signaling domain from FcεRIγ have been shown to deliver a potent signal for T cell activation and function.


  • Clone
  • GPA7
  • Host
  • Camelid
  • Target Species
  • Human
  • Gene Name
  • gp100 (280–288) peptide
  • Gene ID
  • 6490
  • Synonyms
  • gp100 (280–288) peptide; YLEPGPVTA

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive the latest news and insights to your inbox.